Celldex Therapeutics, Inc.
CLDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Celldex Therapeutics, Inc. (CLDX) is listed under Biotechnology. The $2.30B market capitalization puts CLDX squarely in mid-cap range for its industry. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Market Cap
$2.30B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-6.88
EPS (TTM)
$-4.40
EPS (Fwd)
$-4.25
ROE
-43.9%
ROA
-27.6%
Cash
$717.6M
Total Debt
$4.9M
Free CF
-$133.1M
52W Change
9.5%
Annual Financials
Cash vs Debt
Where CLDX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CLDX finished 14.02% below its 150-day moving average ($34.51) and 8.74% below its 200-day moving average ($32.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLDX overbought or oversold?
At the October 20, 2026 close, CLDX's RSI(14) was 42.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $717.6M in cash and $4.9M in debt, CLDX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$133.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $2.4M to $1.5M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLDX.